Critical decisions over two months and four sitting weeks

A group of UK researchers, leading biopharmaceutical companies and industry groups have called on the country's National Health Service to take a dramatic step forward by introducing genetic profiling of every patient's cancer following diagnosis and during treatment.

Starpharma has announced a new research agreement under which it will design and synthesise a number of DEP dendrimer conjugates and provide them to MSD.

BIO president and CEO Dr Michelle McMurry-Heath said the only certain outcome from the change will be "fewer cures for patients."

The industry is significantly focused on the implications of next April's 'catch-up' statutory price reductions but it might need to take a wider view of what are much broader and fundamental changes to the policy infrastructure of the PBS that will have an enduring impact.

The hearing's presiding officer challenged the line of questioning, saying an outcome that 'disadvantages' the Commonwealth is not relevant to the hearing or Freedom of Information laws.

The Pharma Australia Inclusion Group has launched a new ‘pay it forward’ initiative at yesterday's first workshop of its 2022-23 diversity and inclusion program.

The TGA has registered Roche's eye therapy VABYSMO (faricimab) for the treatment of neovascular or 'wet' age-related macular degeneration and diabetic macular oedema.

The Victorian government has provided $5.4 million to a collaboration involving researchers from Monash University and the University of Melbourne to establish the state's mRNA Innovation Hub.

The first day of a critical legal hearing has seen more information revealed about the process concerning the consideration of funding for a breast cancer tumour profiling test but the suggestion witnesses were being evasive.

One staggering admission at yesterday's Administrative Appeals Tribunal hearing was from Professor Robyn Ward on the process for the destruction of documents.

The US research-based pharmaceutical industry has slammed Senate endorsement of the Biden administration's plan that allows the government to negotiate and set prices for some prescription medicines.

Australia’s Blood Cancer Taskforce has launched six new Optimal Care Pathways for blood treatment and care.

Sanofi Australia has started the process of installing a system of over 1,500 solar panels across its Brisbane manufacturing site.

It is an incredibly embarrassing situation for an industry trying to establish a working relationship with a new government but it could get worse given what else could be lurking in these agreements and the fact the exercise of 'discretion' will come with a cost.

The evidence suggests the industry simply does not understand the mechanics and inner workings of the institutionalised policy environment in which it operates.

In mid-2020, in the months leading up to the 2020-21 Budget, former health minister Greg Hunt invited the industry's two main associations to start the negotiation for new agreements to follow those that were due to expire in mid-2022. The offer was clearly a trap.

The number of applications seeking the exercise of ministerial discretion to vary or waive next April's 'catch-up' reductions needs to be made public as a matter of principle given the potential implications for a critical public health program.

The federal government's 'rapid review' of its predecessor's decision to defund NPS Medicinewise as the steward of the QUM arm of the National Medicines Policy has been nothing if not rapid.

The Australian maker of the rapid onset painkiller known as the 'green whistle' has announced a significant capital raise it will use to fund its growth and expansion.